This research combination pairs CJC-1295 (No DAC), a modified growth hormone–releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue. Together, they are studied for their ability to stimulate pulsatile growth hormone release in controlled laboratory models without prolonged receptor binding.
CJC-1295 (No DAC) is frequently examined for its role in mimicking endogenous GH release patterns, while Ipamorelin selectively targets ghrelin receptors with minimal impact on cortisol or prolactin pathways. This makes the combination of interest in endocrine and regenerative signaling research.
Laboratories utilize this peptide pairing when investigating muscle recovery pathways, sleep cycle modulation, tissue regeneration signaling, and metabolic hormone research. Its short-acting profile allows for more natural GH pulse modeling compared to long-acting analogs.
Each vial is prepared to meet research-grade standards suitable for experimental protocols.
Disclaimer:
For laboratory research purposes only. Not for human consumption.
Reviews
There are no reviews yet.